Umbilical cord blood and cord tissue banking as somatic stem cell resources to support medical cell modalities

Table 1 Clinical trials using allogeneic umbilical cord-derived mesenchymal stromal cells for acute GVHD

Authors	Disease	Phase	Patients number	Age (range) year	Cell number	Frequency, interval	Results	Adverse event
Soder RP., et al. [17] (2020)	Steroid-resistant aGVHD	1	10	35–73	2 × 10⁶ cells/kg, 10 × 10⁶ cells/kg	Day 0, day 7	ORR: 70% (4 CR, 3 PR). Day 100/180 survival: 90% /60%,	No AE
Nagamura-Inoue, T., et al. [10] (2022)	Steroid-resistant aGVHD	1	7	25–62	1 × 10⁶ells/kg, 2 × 10⁶/kg	Twice/week, for 2 weeks. 2 additional weeks for PR or MR patients with no SAE	ORR: 71.4% (3 CR, 2PR, 1 MR,1 NR), over 28 days continuous CR/PR: 100%	no SAE

All MSCs were injected intravenously
Day 0 the first administration day
AE adverse event, aGVHD acute graft-versus-host disease, CR complete response, MR mixed response, NR no response, ORR overall response rate, PR partial response, SAE severe adverse event

ISSN: 1880-8190